Collegium Pharmaceutical Q1 Earnings Call Highlights
Key takeaways
- Collegium Pharmaceutical Q1 Earnings Call Highlights Market Beat Fri, May 8, 2026 at 12:42 AM GMT+7 7 min read COLL Collegium Pharmaceutical logo 5 Hot Stocks With Summer Buybacks You Can Cash In On
- Total net product revenues were $193.5 million, up 9% year-over-year, according to CFO Colleen Tupper.
- → Berkshire Hathaway’s Record Cash Hoard: Why and What s Next?
Collegium Pharmaceutical Q1 Earnings Call Highlights Market Beat Fri, May 8, 2026 at 12:42 AM GMT+7 7 min read COLL Collegium Pharmaceutical logo 5 Hot Stocks With Summer Buybacks You Can Cash In On
Collegium Pharmaceutical (NASDAQ:COLL) reported first-quarter 2026 results highlighting continued growth in its ADHD franchise led by JORNAY PM, steady performance from its pain portfolio, and progress toward its planned acquisition of AZSTARYS. Management said the company remains focused on three 2026 priorities: driving JORNAY growth, maximizing the durability of the pain portfolio, and executing a capital deployment strategy that includes business development, debt repayment, and opportunistic share repurchases.
Total net product revenues were $193.5 million, up 9% year-over-year, according to CFO Colleen Tupper. JORNAY PM generated $38.9 million in net revenue, up 36% year-over-year, while the pain portfolio produced $154.6 million, up 4% year-over-year, CEO Vikram Karnani said.